Research Article

You have free access to this content

microRNA146a Expression in Lupus Patients With and Without Renal Complications

  1. Hashad DI1,*,
  2. Abdelmagid MH2,
  3. Elsherif SH3

Article first published online: 24 JAN 2012

DOI: 10.1002/jcla.20501

Issue

Journal of Clinical Laboratory Analysis

Journal of Clinical Laboratory Analysis

Volume 26, Issue 1, pages 35–40, January 2012

Additional Information

How to Cite

Hashad, D., Abdelmagid, M. and Elsherif, S. (2012), microRNA146a Expression in Lupus Patients With and Without Renal Complications. J. Clin. Lab. Anal., 26: 35–40. doi: 10.1002/jcla.20501

Author Information

  1. 1

    Clinical Pathology Department, Alexandria, Egypt

  2. 2

    Rheumatology Department, Alexandria, Egypt

  3. 3

    Physical Medicine, Rheumatology and Rehabilitation Department Faculty of Medicine, Alexandria University, Alexandria, Egypt

*Correspondence to: Doaa Hashad, Lecturer of Clinical Pathology, Department of Clinical Pathology, Faculty of Medicine, Alexandria University Azarita, Alexandria Egypt.

Publication History

  1. Issue published online: 24 JAN 2012
  2. Article first published online: 24 JAN 2012
  3. Manuscript Accepted: 16 SEP 2011
  4. Manuscript Received: 8 JUL 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (483K)

REFERENCES

  • 1
    Hakkim A, Fürnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. PNAS 2010;107:9813–9818.
  • 2
    Mok C. Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol 2010;2010:1–11.
  • 3
    Soifer H, Rossi J, Sćtrom P. MicroRNAs in disease and potential therapeutic applications. Mol Ther 2007;12:2070–2079.
  • 4
    Sonkoly E, Pivarcsi A. microRNAs in inflammation. Int Rev Immunol 2009;28:535–561.
  • 5
    Chan EK, Satoh M, Pauley KM. Contrast in aberrant microRNA expression in systemic lupus erythematosus and rheumatoid arthritis: is microRNA-146 all we need? Arthritis Rheum 2009;60:912–915.
  • 6
    Dai Y, Huang YS, Tang M, et al. Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus 2007;16:939–946.
  • 7
    Tang Y, Luo X, Cui H, et al. MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009;60:1065–1075.
  • 8
    Calin GA, Croce CM. microRNA signatures in human cancers. Nat Rev Cancer 2006;6:857–866.
  • 9
    Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009;32:189–194.
  • 10
    Hochberg MA. Updating the ACR revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:172.
  • 11
    Petri M. Disease activity assessment in SLE: do we have the right instruments? Ann Rheum Dis 2007;66:iii61–iii64.
  • 12
    Lacelle C, Riol H, Xu S, et al. Blood sample processing for the study of age-dependent gene expression in peripheral blood mononuclear cells. J Gerontol A Biol Sci Med Sci 2002;57:B285–B287.
  • 13
    Nakasa T, Miyaki S, Okubo A, et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum 2008;58:1284–1292.
  • 14
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCt method. Diagn Mol Pathol 2001;25:402–408.
  • 15
    Dai Y, Sui W, Lan H, et al. Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int 2009;29:749–754.
  • 16
    Te JL, Dozmorov IM, Guthridge JM, et al. Identification of unique microRNA signature associated with lupus nephritis. PLoS ONE 2010;5:1–7.
  • 17
    Sonkoly E, Pivarcsi A. microRNAs in inflammation. Int Rev Immunol 2009;28:535–561.
  • 18
    López-Hoyos M, Cabeza R, Martínez-Taboada VM. Clinical disease activity and titers of anti-dsDNA antibodies measured by an automated immunofluorescence assay in patients with systemic lupus erythematosus. Lupus 2005;14:505–509.
  • 19
    Niewol T, Swedler W. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005;24:178–181.
  • 20
    Niewold T, Clark D, Salloum R, Poole B. Interferon alpha in systemic lupus erythematosus. J Biomed Biotechnol 2010;2010:1–8.
  • 21
    Bagavanta H, Fua S. Pathogenesis of kidney disease in systemic lupus erythematosus. Curr Opin Rheumatol 2009;21:489–494.
  • 22
    Dall'Era MC, Cardarelli PM, Preston BT, Witte A, Davis Jr JC. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005;64:1692–1697.
  • 23
    Bengtsson A. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664–671.
View Full Article (HTML) Get PDF (483K)